Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical outcomes of refined transepithelial photorefractive keratectomy in asymmetric astigmatism

Poster Details

First Author: S. Adib-Moghaddam IRAN

Co Author(s): S. Soleyman-Jahi   S. Tofighi   G. Tefagh              

Abstract Details


To evaluate quantitative and qualitative visual outcomes of Transepithelial Photorefractive Keratectomy (TransPRK) in myopic patients with asymmetric astigmatism.


Bina Eye Hospital, Tehran, Iran


Sixty four eyes (32 patients) with myopia and asymmetric astigmatism were recruited in this 18-month prospective study. Fifty eyes (78.13%) belonged to female and 14 eyes (21.89%) to male patients. Mean age of the patients was 26.95±4.36. All of the eyes underwent one-step refined TransPRK by the same refractive surgeon (S.A.M.) using SCHWIND AMARIS 500 laser. Patients were followed for 18 months. Visual acuity, refraction, contrast sensitivity (CS) and spherical, coma and trefoil higher order aberration (HOA)s were assessed before and after the operation.


Mean preoperative spherical equivalent, astigmatism, logMAR UDVA and CDVA were -2.71±2.10, 1.33±1.05, 0.69±0.47 and 0.03±0.27, respectively and by 18 months follow up they improved to 0.01±0.09, 0.01±0.07, -0.07±0.16 and -0.12±0.06, respectively (P < 0.001 for all). All but one eye (98.31%) was within target±0.5 D of refraction. No eye lost two or more lines of preoperative CDVA. Both photopic and mesopic CSs improved (P=0.04 and 0.01, respectively). Ocular wave-front spherical aberration improved (P < 0.001); other ocular or corneal wave-front HOAs did not show a significant change.


This long-term data demonstrates efficacy and safety of refined TransPRK by AMARIS 500 laser in correction of myopia and asymmetric astigmatism.

Financial Disclosure:


Back to Poster listing